 GAITHERSBURG, Md., Jan. 03, 2022 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Companys novel, investigational GLP-1Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis NASH, the most severe form of non-alcoholic fatty liver disease NAFLD. The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows: 